Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anika Therapeutics (ANIK) EBIT Margin (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed EBIT Margin for 16 consecutive years, with 2.11% as the latest value for Q4 2025.

  • On a quarterly basis, EBIT Margin fell 8879.0% to 2.11% in Q4 2025 year-over-year; TTM through Dec 2025 was 9.8%, a 2794.0% decrease, with the full-year FY2025 number at 9.8%, down 554.0% from a year prior.
  • EBIT Margin was 2.11% for Q4 2025 at Anika Therapeutics, up from 11.62% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 90.9% in Q4 2024 to a low of 852.09% in Q4 2023.
  • A 5-year average of 74.6% and a median of 9.16% in 2022 define the central range for EBIT Margin.
  • Peak YoY movement for EBIT Margin: plummeted -56309bps in 2022, then skyrocketed 94299bps in 2024.
  • Anika Therapeutics' EBIT Margin stood at 25.47% in 2021, then plummeted by -2211bps to 588.55% in 2022, then plummeted by -45bps to 852.09% in 2023, then surged by 111bps to 90.9% in 2024, then crashed by -98bps to 2.11% in 2025.
  • Per Business Quant, the three most recent readings for ANIK's EBIT Margin are 2.11% (Q4 2025), 11.62% (Q3 2025), and 14.81% (Q2 2025).